Skip to content
Screener

Agios Pharmaceuticals AGIO Inventories

Inventories at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.74B0.0%
Pfizer logo
PfizerPFE
$2.46B-11.9%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.77B+17.7%
Incyte logo
IncyteINCY
$345.03M-6.3%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.65M+150%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$1.78B+33.0%

Other financials

Income statement

See full
Revenue$44.7M+259%
Gross profit$41.7M+288%
Operating income-$110.6M+13.0%
Net income-$100.7M+10.1%
EPS (diluted)-$1.69+12.4%

Balance sheet

See full
Cash & equivalents$99.6M+23.2%
Total debt$31.2M-36.1%
Total equity$1.0B-25.1%
Total assets$1.1B-24.7%

Cash flow

See full
Operating cash flow-$57.3M+25.7%
CapEx$1.2M+38.5%
Free cash flow-$58.5M+25.0%

Valuation

See full
Market cap$1.93B-5.5%
Enterprise value$1.86B-7.4%
P/S19.6×-30.3×

Profitability

See full
Gross margin92%+3.8pp
Operating margin-466.8%-173pp
Net margin-418.2%—
FCF margin-371.4%-143pp

Returns & leverage

See full
Return on equity-34.3%—
Debt / equity0×0.0×
Current ratio10.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryNoncurrent.

The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:56 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001439222-26-000118
(In thousands)June 30,2026December 31, 2025
Raw materials$374$88
Work-in-process32,00730,253
Finished goods3,3712,579
Total inventory$35,752$32,920
Balance Sheet Classification:
Inventory$30,152$32,920
Other non-current assets5,600—
Total inventory$35,752$32,920

Item 1. Financial Statements (Unaudited)

FAQ

What is Agios Pharmaceuticals's inventories?
Agios Pharmaceuticals (AGIO) reported inventories of $5.6M in Q2 2026.
How has Agios Pharmaceuticals's inventories changed year-over-year?
Agios Pharmaceuticals's inventories decreased by 81.8% year-over-year, from $30.85M to $5.6M.
What is the long-term trend for Agios Pharmaceuticals's inventories?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's inventories has grown at a -100.0% compound annual growth rate (CAGR), from $14.7M to $0.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.

Ask your AI about Agios Pharmaceuticals's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude